 | • レポートコード：GIR-2104Z04702 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、トキソプラズマ症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。トキソプラズマ症治療薬の種類別市場規模（注射、錠剤、その他）、用途別市場規模（慢性トキソプラズマ症治療、急性トキソプラズマ症治療、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・トキソプラズマ症治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Turing Pharmaceutical、Snowdon、Guangzhou Baiyunshan Pharmaceutical Co., Ltd.、Taj Pharmaceuticals Limited、Glaxo Smithkline Pharmaceuticals Ltd. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：注射、錠剤、その他 ・用途別分析2016年-2026年：慢性トキソプラズマ症治療、急性トキソプラズマ症治療、その他 ・トキソプラズマ症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・トキソプラズマ症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・トキソプラズマ症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・トキソプラズマ症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・トキソプラズマ症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Drugs for Toxoplasmosis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Drugs for Toxoplasmosis size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Drugs for Toxoplasmosis market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Drugs for Toxoplasmosis market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Injection
Tablet
Others
Market segment by Application can be divided into
Chronic Toxoplasmosis Treatment
Acute Toxoplasmosis Treatment
Other
The key market players for global Drugs for Toxoplasmosis market are listed below:
Turing Pharmaceutical
Snowdon
Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
Taj Pharmaceuticals Limited
Glaxo Smithkline Pharmaceuticals Ltd.
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Drugs for Toxoplasmosis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Toxoplasmosis Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Injection
1.2.3 Tablet
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Toxoplasmosis Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Chronic Toxoplasmosis Treatment
1.3.3 Acute Toxoplasmosis Treatment
1.3.4 Other
1.4 Global Drugs for Toxoplasmosis Market Size & Forecast
1.4.1 Global Drugs for Toxoplasmosis Sales in Value (2016-2026))
1.4.2 Global Drugs for Toxoplasmosis Sales in Volume (2016-2026)
1.4.3 Global Drugs for Toxoplasmosis Price by Type (2016-2026) & (USD/MT)
1.5 Global Drugs for Toxoplasmosis Production Capacity Analysis
1.5.1 Global Drugs for Toxoplasmosis Total Production Capacity (2016-2026)
1.5.2 Global Drugs for Toxoplasmosis Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Drugs for Toxoplasmosis Market Drivers
1.6.2 Drugs for Toxoplasmosis Market Restraints
1.6.3 Drugs for Toxoplasmosis Trends Analysis
2 Manufacturers Profiles
2.1 Turing Pharmaceutical
2.1.1 Turing Pharmaceutical Details
2.1.2 Turing Pharmaceutical Major Business
2.1.3 Turing Pharmaceutical Drugs for Toxoplasmosis Product and Services
2.1.4 Turing Pharmaceutical Drugs for Toxoplasmosis Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Snowdon
2.2.1 Snowdon Details
2.2.2 Snowdon Major Business
2.2.3 Snowdon Drugs for Toxoplasmosis Product and Services
2.2.4 Snowdon Drugs for Toxoplasmosis Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
2.3.1 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Details
2.3.2 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Major Business
2.3.3 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Product and Services
2.3.4 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Taj Pharmaceuticals Limited
2.4.1 Taj Pharmaceuticals Limited Details
2.4.2 Taj Pharmaceuticals Limited Major Business
2.4.3 Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Product and Services
2.4.4 Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Glaxo Smithkline Pharmaceuticals Ltd.
2.5.1 Glaxo Smithkline Pharmaceuticals Ltd. Details
2.5.2 Glaxo Smithkline Pharmaceuticals Ltd. Major Business
2.5.3 Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Product and Services
2.5.4 Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Drugs for Toxoplasmosis Sales by Manufacturer
3.1 Global Drugs for Toxoplasmosis Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Drugs for Toxoplasmosis Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Drugs for Toxoplasmosis
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Toxoplasmosis Manufacturer Market Share
3.4.2 Top 6 Drugs for Toxoplasmosis Manufacturer Market Share
3.5 Global Drugs for Toxoplasmosis Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Drugs for Toxoplasmosis Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Drugs for Toxoplasmosis Market Size by Region
4.1.1 Global Drugs for Toxoplasmosis Sales in Volume by Region (2016-2026)
4.1.2 Global Drugs for Toxoplasmosis Revenue by Region (2016-2026)
4.2 North America Drugs for Toxoplasmosis Revenue (2016-2026)
4.3 Europe Drugs for Toxoplasmosis Revenue (2016-2026)
4.4 Asia-Pacific Drugs for Toxoplasmosis Revenue (2016-2026)
4.5 South America Drugs for Toxoplasmosis Revenue (2016-2026)
4.6 Middle East and Africa Drugs for Toxoplasmosis Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Drugs for Toxoplasmosis Sales in Volume by Type (2016-2026)
5.2 Global Drugs for Toxoplasmosis Revenue by Type (2016-2026)
5.3 Global Drugs for Toxoplasmosis Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Drugs for Toxoplasmosis Sales in Volume by Application (2016-2026)
6.2 Global Drugs for Toxoplasmosis Revenue by Application (2016-2026)
6.3 Global Drugs for Toxoplasmosis Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Drugs for Toxoplasmosis Sales by Type (2016-2026)
7.2 North America Drugs for Toxoplasmosis Sales by Application (2016-2026)
7.3 North America Drugs for Toxoplasmosis Market Size by Country
7.3.1 North America Drugs for Toxoplasmosis Sales in Volume by Country (2016-2026)
7.3.2 North America Drugs for Toxoplasmosis Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Drugs for Toxoplasmosis Sales by Type (2016-2026)
8.2 Europe Drugs for Toxoplasmosis Sales by Application (2016-2026)
8.3 Europe Drugs for Toxoplasmosis Market Size by Country
8.3.1 Europe Drugs for Toxoplasmosis Sales in Volume by Country (2016-2026)
8.3.2 Europe Drugs for Toxoplasmosis Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Drugs for Toxoplasmosis Sales by Type (2016-2026)
9.2 Asia-Pacific Drugs for Toxoplasmosis Sales by Application (2016-2026)
9.3 Asia-Pacific Drugs for Toxoplasmosis Market Size by Region
9.3.1 Asia-Pacific Drugs for Toxoplasmosis Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Drugs for Toxoplasmosis Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Drugs for Toxoplasmosis Sales by Type (2016-2026)
10.2 South America Drugs for Toxoplasmosis Sales by Application (2016-2026)
10.3 South America Drugs for Toxoplasmosis Market Size by Country
10.3.1 South America Drugs for Toxoplasmosis Sales in Volume by Country (2016-2026)
10.3.2 South America Drugs for Toxoplasmosis Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Drugs for Toxoplasmosis Sales by Type (2016-2026)
11.2 Middle East & Africa Drugs for Toxoplasmosis Sales by Application (2016-2026)
11.3 Middle East & Africa Drugs for Toxoplasmosis Market Size by Country
11.3.1 Middle East & Africa Drugs for Toxoplasmosis Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Drugs for Toxoplasmosis Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Drugs for Toxoplasmosis Typical Distributors
12.3 Drugs for Toxoplasmosis Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Drugs for Toxoplasmosis Revenue by Type, (USD Million), 2021-2026
Table 2. Global Drugs for Toxoplasmosis Revenue by Application, (USD Million), 2021-2026
Table 3. Turing Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 4. Turing Pharmaceutical Major Business
Table 5. Turing Pharmaceutical Drugs for Toxoplasmosis Product and Services
Table 6. Turing Pharmaceutical Drugs for Toxoplasmosis Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Snowdon Basic Information, Manufacturing Base and Competitors
Table 8. Snowdon Major Business
Table 9. Snowdon Drugs for Toxoplasmosis Product and Services
Table 10. Snowdon Drugs for Toxoplasmosis Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 12. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Major Business
Table 13. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Product and Services
Table 14. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Taj Pharmaceuticals Limited Basic Information, Manufacturing Base and Competitors
Table 16. Taj Pharmaceuticals Limited Major Business
Table 17. Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Product and Services
Table 18. Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Glaxo Smithkline Pharmaceuticals Ltd. Basic Information, Manufacturing Base and Competitors
Table 20. Glaxo Smithkline Pharmaceuticals Ltd. Major Business
Table 21. Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Product and Services
Table 22. Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Global Drugs for Toxoplasmosis Sales by Manufacturer (2019-2021e) & (K MT)
Table 24. Global Drugs for Toxoplasmosis Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 25. Market Position of Manufacturers in Drugs for Toxoplasmosis, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 26. Global Drugs for Toxoplasmosis Production Capacity by Company, (K MT): 2020 VS 2021
Table 27. Head Office and Drugs for Toxoplasmosis Production Site of Key Manufacturer
Table 28. Global Drugs for Toxoplasmosis Sales by Region (2016-2021e) & (K MT)
Table 29. Global Drugs for Toxoplasmosis Sales by Region (2021-2026) & (K MT)
Table 30. Global Drugs for Toxoplasmosis Revenue by Region (2016-2021e) & (USD Million)
Table 31. Global Drugs for Toxoplasmosis Revenue by Region (2021-2026) & (USD Million)
Table 32. Global Drugs for Toxoplasmosis Sales by Type (2016-2021e) & (K MT)
Table 33. Global Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K MT)
Table 34. Global Drugs for Toxoplasmosis Revenue by Type (2016-2021e) & (USD Million)
Table 35. Global Drugs for Toxoplasmosis Revenue by Type (2021-2026) & (USD Million)
Table 36. Global Drugs for Toxoplasmosis Price by Type (2016-2021e) & (USD/MT)
Table 37. Global Drugs for Toxoplasmosis Price by Type (2021-2026) & (USD/MT)
Table 38. Global Drugs for Toxoplasmosis Sales by Application (2016-2021e) & (K MT)
Table 39. Global Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K MT)
Table 40. Global Drugs for Toxoplasmosis Revenue by Application (2016-2021e) & (USD Million)
Table 41. Global Drugs for Toxoplasmosis Revenue by Application (2021-2026) & (USD Million)
Table 42. Global Drugs for Toxoplasmosis Price by Application (2016-2021e) & (USD/MT)
Table 43. Global Drugs for Toxoplasmosis Price by Application (2021-2026) & (USD/MT)
Table 44. North America Drugs for Toxoplasmosis Sales by Country (2016-2021e) & (K MT)
Table 45. North America Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K MT)
Table 46. North America Drugs for Toxoplasmosis Revenue by Country (2016-2021e) & (USD Million)
Table 47. North America Drugs for Toxoplasmosis Revenue by Country (2021-2026) & (USD Million)
Table 48. North America Drugs for Toxoplasmosis Sales by Type (2016-2021e) & (K MT)
Table 49. North America Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K MT)
Table 50. North America Drugs for Toxoplasmosis Sales by Application (2016-2021e) & (K MT)
Table 51. North America Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K MT)
Table 52. Europe Drugs for Toxoplasmosis Sales by Country (2016-2021e) & (K MT)
Table 53. Europe Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K MT)
Table 54. Europe Drugs for Toxoplasmosis Revenue by Country (2016-2021e) & (USD Million)
Table 55. Europe Drugs for Toxoplasmosis Revenue by Country (2021-2026) & (USD Million)
Table 56. Europe Drugs for Toxoplasmosis Sales by Type (2016-2021e) & (K MT)
Table 57. Europe Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K MT)
Table 58. Europe Drugs for Toxoplasmosis Sales by Application (2016-2021e) & (K MT)
Table 59. Europe Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K MT)
Table 60. Asia-Pacific Drugs for Toxoplasmosis Sales by Region (2016-2021e) & (K MT)
Table 61. Asia-Pacific Drugs for Toxoplasmosis Sales by Region (2021-2026) & (K MT)
Table 62. Asia-Pacific Drugs for Toxoplasmosis Revenue by Region (2016-2021e) & (USD Million)
Table 63. Asia-Pacific Drugs for Toxoplasmosis Revenue by Region (2021-2026) & (USD Million)
Table 64. Asia-Pacific Drugs for Toxoplasmosis Sales by Type (2016-2021e) & (K MT)
Table 65. Asia-Pacific Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K MT)
Table 66. Asia-Pacific Drugs for Toxoplasmosis Sales by Application (2016-2021e) & (K MT)
Table 67. Asia-Pacific Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K MT)
Table 68. South America Drugs for Toxoplasmosis Sales by Country (2016-2021e) & (K MT)
Table 69. South America Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K MT)
Table 70. South America Drugs for Toxoplasmosis Revenue by Country (2016-2021e) & (USD Million)
Table 71. South America Drugs for Toxoplasmosis Revenue by Country (2021-2026) & (USD Million)
Table 72. South America Drugs for Toxoplasmosis Sales by Type (2016-2021e) & (K MT)
Table 73. South America Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K MT)
Table 74. South America Drugs for Toxoplasmosis Sales by Application (2016-2021e) & (K MT)
Table 75. South America Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K MT)
Table 76. Middle East & Africa Drugs for Toxoplasmosis Sales by Country (2016-2021e) & (K MT)
Table 77. Middle East & Africa Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K MT)
Table 78. Middle East & Africa Drugs for Toxoplasmosis Revenue by Country (2016-2021e) & (USD Million)
Table 79. Middle East & Africa Drugs for Toxoplasmosis Revenue by Country (2021-2026) & (USD Million)
Table 80. Middle East & Africa Drugs for Toxoplasmosis Sales by Type (2016-2021e) & (K MT)
Table 81. Middle East & Africa Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K MT)
Table 82. Middle East & Africa Drugs for Toxoplasmosis Sales by Application (2016-2021e) & (K MT)
Table 83. Middle East & Africa Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K MT)
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Drugs for Toxoplasmosis Typical Distributors
Table 87. Drugs for Toxoplasmosis Typical Customers
List of Figures
Figure 1. Drugs for Toxoplasmosis Picture
Figure 2. Global Drugs for Toxoplasmosis Sales Market Share by Type in 2020
Figure 3. Injection
Figure 4. Tablet
Figure 5. Others
Figure 6. Global Drugs for Toxoplasmosis Sales Market Share by Application in 2020
Figure 7. Chronic Toxoplasmosis Treatment
Figure 8. Acute Toxoplasmosis Treatment
Figure 9. Other
Figure 10. Global Drugs for Toxoplasmosis Market Size, (USD Million) & (K MT): 2020 VS 2021 VS 2026
Figure 11. Global Drugs for Toxoplasmosis Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. United States Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Canada Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Mexico Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Germany Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. France Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. United Kingdom Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Russia Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Italy Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. China Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Japan Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Korea Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. India Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Southeast Asia Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Australia Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Brazil Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Egypt Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Saudi Arabia Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. South Africa Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Turkey Drugs for Toxoplasmosis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Global Drugs for Toxoplasmosis Sales (2016-2026) & (K MT)
Figure 32. Global Drugs for Toxoplasmosis Production Capacity (2016-2026) & (K MT)
Figure 33. Global Drugs for Toxoplasmosis Production Capacity by Geographic Region: 2020 VS 2021
Figure 34. Drugs for Toxoplasmosis Market Drivers
Figure 35. Drugs for Toxoplasmosis Market Restraints
Figure 36. Drugs for Toxoplasmosis Market Trends
Figure 37. Global Drugs for Toxoplasmosis Sales Market Share by Manufacturer in 2020
Figure 38. Global Drugs for Toxoplasmosis Revenue Market Share by Manufacturer in 2020
Figure 39. Drugs for Toxoplasmosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 40. Top 3 Drugs for Toxoplasmosis Manufacturer (Revenue) Market Share in 2020
Figure 41. Top 6 Drugs for Toxoplasmosis Manufacturer (Revenue) Market Share in 2020
Figure 42. Global Drugs for Toxoplasmosis Sales Market Share by Region (2016-2026)
Figure 43. Global Drugs for Toxoplasmosis Revenue Market Share by Region (2016-2026)
Figure 44. North America Drugs for Toxoplasmosis Revenue (2016-2026) & (USD Million)
Figure 45. Europe Drugs for Toxoplasmosis Revenue (2016-2026) & (USD Million)
Figure 46. Asia-Pacific Drugs for Toxoplasmosis Revenue (2016-2026) & (USD Million)
Figure 47. South America Drugs for Toxoplasmosis Revenue (2016-2026) & (USD Million)
Figure 48. Middle East & Africa Drugs for Toxoplasmosis Revenue (2016-2026) & (USD Million)
Figure 49. Global Drugs for Toxoplasmosis Sales Market Share by Type (2016-2026)
Figure 50. Global Drugs for Toxoplasmosis Revenue Market Share by Type (2016-2026)
Figure 51. Global Drugs for Toxoplasmosis Price by Type (2016-2026) & (USD/MT)
Figure 52. Global Drugs for Toxoplasmosis Sales Market Share by Application (2016-2026)
Figure 53. Global Drugs for Toxoplasmosis Revenue Market Share by Application (2016-2026)
Figure 54. Global Drugs for Toxoplasmosis Price by Application (2016-2026) & (USD/MT)
Figure 55. North America Drugs for Toxoplasmosis Sales Market Share by Country (2016-2026)
Figure 56. North America Drugs for Toxoplasmosis Revenue Market Share by Country (2016-2026)
Figure 57. North America Drugs for Toxoplasmosis Sales Market Share by Type (2016-2026)
Figure 58. North America Drugs for Toxoplasmosis Sales Market Share by Application (2016-2026)
Figure 59. Europe Drugs for Toxoplasmosis Sales Market Share by Country (2016-2026)
Figure 60. Europe Drugs for Toxoplasmosis Revenue Market Share by Country (2016-2026)
Figure 61. Europe Drugs for Toxoplasmosis Sales Market Share by Type (2016-2026)
Figure 62. Europe Drugs for Toxoplasmosis Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Drugs for Toxoplasmosis Revenue Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share by Application (2016-2026)
Figure 67. South America Drugs for Toxoplasmosis Sales Market Share by Country (2016-2026)
Figure 68. South America Drugs for Toxoplasmosis Revenue Market Share by Country (2016-2026)
Figure 69. South America Drugs for Toxoplasmosis Sales Market Share by Type (2016-2026)
Figure 70. South America Drugs for Toxoplasmosis Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Drugs for Toxoplasmosis Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Drugs for Toxoplasmosis Revenue Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Drugs for Toxoplasmosis Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Drugs for Toxoplasmosis Sales Market Share by Application (2016-2026)
Figure 75. Sales Channel: Direct Channel vs Indirect Channel
Figure 76. Methodology
Figure 77. Research Process and Data Source
世界のトキソプラズマ症検査市場規模・現状・予測（2021年-2027年） The term toxoplasmosis refers to the infectious disease caused by the parasite Toxoplasma gondii. It may cause acute or chronic infection. Currently, North America dominates the global toxoplasmosis testing market, followed by Europe. This is due to the rising prevalence of infectious diseases and i…- 世界のトキソプラズマ症検査市場 2021：企業別、地域別、種類・用途別 The Toxoplasmosis Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulatio…
- 世界の肺がん治療薬市場規模・現状・予測（2021年-2027年） Lung Cancer Treatment Drugs are durgs used to cure lung cancer. In the coming years, it is expected that the global Lung Cancer Treatment Drugs market will advance with higher growth rate as compared to previous years. Factors such as Smoking, Rising cases of infections, Rising rates of fast growing…
- 世界の眼瞼炎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Blepharitis Treatment Drugs Market The global Blepharitis Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity…
- 世界の膵臓がん治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Pancreatic Cancer Treatment Drugs Market The global Pancreatic Cancer Treatment Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…